ALGN vs UTHR
Align Technology vs United Therapeutics — AI-powered side-by-side comparison
ALGN
Align Technology
62
Buy
VS
UTHR
United Therapeutics
67
Buy
| Metric | ALGN | UTHR |
|---|
| AI Score |
62
|
67
|
| Price |
$173.70
|
$538.75
|
| P/E Ratio |
30.15×
|
17.82×
|
| ROE |
10.1%
|
18.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
66.5%
|
86.1%
|
| Debt / Equity |
0.03×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
50.8
|
66.9
|
| Beta |
1.669
|
0.58
|
| Expected Upside |
+9.2%
|
+4.6%
|
AI Committee View
Current Innellis committee reasoning for ALGN versus UTHR.
UTHR leads by 5 points.
UTHR scores 67/100 (Buy) versus ALGN at 62/100 (Buy).
ALGN Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
- Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
Bear Case
- P/E of 29.8 is moderate-to-rich — Value
- EPS declining -2.5% YoY despite any revenue growth — Growth
- MACD histogram negative -- bearish momentum — Technical
UTHR Committee View
83% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- ROE of 20.2% shows genuine earnings power backing the valuation — Value
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Lower Highs / Lower Lows structure confirms bearish price action.
- Risk/reward is unfavorable: 15.0% downside vs 4.6% upside.